Published in Eur J Neurosci on September 01, 2001
Viral vector-mediated overexpression of estrogen receptor-alpha in striatum enhances the estradiol-induced motor activity in female rats and estradiol-modulated GABA release. J Neurosci (2009) 0.94
Estrogen receptor α and G-protein coupled estrogen receptor 1 are localized to GABAergic neurons in the dorsal striatum. Neurosci Lett (2016) 0.79
Effects of propofol on the dopamine, metabolites and GABAA receptors in media prefrontal cortex in freely moving rats. Am J Transl Res (2016) 0.75
Dysfunctions of the basal ganglia-cerebellar-thalamo-cortical system produce motor tics in Tourette syndrome. PLoS Comput Biol (2017) 0.75
Mitochondrial complex I deficiency in Parkinson's disease. Lancet (1989) 5.72
Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem (1990) 4.03
The nucleosomal response associated with immediate-early gene induction is mediated via alternative MAP kinase cascades: MSK1 as a potential histone H3/HMG-14 kinase. EMBO J (1999) 3.58
Phosphoacetylation of histone H3 on c-fos- and c-jun-associated nucleosomes upon gene activation. EMBO J (2000) 3.35
Three tomato genes code for heat stress transcription factors with a region of remarkable homology to the DNA-binding domain of the yeast HSF. EMBO J (1990) 3.01
Evolutionary psychology revisited. Br J Psychiatry (2001) 2.88
Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics. J Med Genet (2008) 2.81
The pathophysiology of extrapyramidal side-effects of neuroleptic drugs. Psychol Med (1980) 2.81
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain (1991) 2.52
Utilization of the rpoB gene as a specific chromosomal marker for real-time PCR detection of Bacillus anthracis. Appl Environ Microbiol (2001) 2.50
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem (1989) 2.44
Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem (1989) 2.26
Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem (1997) 2.10
Relationship between plasma propranolol concentration and relief of essential tremor. J Neurol Neurosurg Psychiatry (1979) 2.04
Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci (2001) 2.04
Acute stress disorder and posttraumatic stress disorder in victims of violent crime. Am J Psychiatry (1999) 1.95
Pharmacological evidence for cerebral dopamine receptor blockade by metoclopramide in rodents. Psychopharmacologia (1975) 1.93
A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J Neurochem (1997) 1.83
Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci Lett (2001) 1.73
Extent of Barrett's metaplasia: a prospective study of the serial change in area of Barrett's measured by quantitative endoscopic imaging. Gastrointest Endosc (1997) 1.72
Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease. J Neurochem (1990) 1.66
Brief psychological interventions ("debriefing") for trauma-related symptoms and the prevention of post traumatic stress disorder. Cochrane Database Syst Rev (2000) 1.65
Does contraversive circling in the 6-OHDA-lesioned rat indicate an ability to induce motor complications as well as therapeutic effects in Parkinson's disease? Exp Neurol (2005) 1.64
Predicting PTSD symptoms in victims of violent crime: the role of shame, anger, and childhood abuse. J Abnorm Psychol (2000) 1.64
A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra. J Neurochem (1989) 1.58
Time course of inhibition of brain nitric oxide synthase by 7-nitro indazole. Neuroreport (1994) 1.56
Effect of metoclopramide on turnover of brain dopamine noradrenaline and 5-hydroxytryptamine. J Pharm Pharmacol (1975) 1.54
Moving from continuous dopaminergic stimulation to continuous drug delivery in the treatment of Parkinson's disease. Eur J Neurol (2012) 1.53
Acute dystonia induced by neuroleptic drugs. Psychopharmacology (Berl) (1986) 1.52
Alpha-tocopherol levels in brain are not altered in Parkinson's disease. Ann Neurol (1992) 1.49
Five-year course and outcome of dysthymic disorder: A prospective, naturalistic follow-up study. Am J Psychiatry (2000) 1.48
Real-time detection of Brucella abortus, Brucella melitensis and Brucella suis. Mol Cell Probes (2001) 1.48
Fear, helplessness, and horror in posttraumatic stress disorder: investigating DSM-IV criterion A2 in victims of violent crime. J Trauma Stress (2000) 1.42
Monoclonal antibody to tumor necrosis factor-alpha modulates hepatocellular Ca2+ homeostasis during hemorrhagic shock in the rat. J Mol Med (Berl) (1999) 1.42
Inhibitors of Cytochrome P-450s and their mechanism of action. Drug Metab Rev (1981) 1.42
Pentoxifylline prevention of altered hepatocyte calcium regulation during hemorrhagic shock/resuscitation. Crit Care Med (1998) 1.40
Increased nigral iron content in postmortem parkinsonian brain. Lancet (1987) 1.39
beta-Adrenoreceptor antagonists in essential tremor. J Neurol Neurosurg Psychiatry (1979) 1.39
Revisiting evolutionary psychology and psychiatry. Br J Psychiatry (2001) 1.38
An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer's disease. J Neurochem (1997) 1.36
Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Ann Neurol (1994) 1.36
Quantitative endoscopy: precise computerized measurement of metaplastic epithelial surface area in Barrett's esophagus. Gastroenterology (1995) 1.36
Renal arterial stenosis in renal allografts: retrospective study of predisposing factors and outcome after percutaneous transluminal angioplasty. Radiology (2001) 1.32
Expression of a gene for a porin-like protein of the OmpA family from Mycobacterium tuberculosis H37Rv. J Bacteriol (1998) 1.30
Glutathione-related enzymes in brain in Parkinson's disease. Ann Neurol (1994) 1.29
Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil--a prospective randomized study. Steroid Withdrawal Study Group. Transplantation (1999) 1.29
The Stretching Window Part Two: Rate of Thermal Decay in Deep Muscle Following 1-MHz Ultrasound. J Athl Train (1996) 1.28
Acetyllysine-binding and function of bromodomain-containing proteins in chromatin. Front Biosci (2001) 1.28
In-vitro inhibition of human erythrocyte acetylcholinesterase by salvia lavandulaefolia essential oil and constituent terpenes. J Pharm Pharmacol (2000) 1.28
L-Dopa methyl ester--a candidate for chronic systemic delivery of L-Dopa in Parkinson's disease. Clin Neuropharmacol (1984) 1.24
The role of D-1 and D-2 receptors. Nature (1980) 1.24
Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: possible mechanisms of formation involving reactive oxygen species. J Neurochem (1998) 1.24
Involvement of inducible nitric oxide synthase in inflammation-induced dopaminergic neurodegeneration. Neuroscience (2002) 1.24
Risk factors for syncope recurrence after a positive tilt-table test in patients with syncope. Circulation (1996) 1.23
Intense oxidative DNA damage promoted by L-dopa and its metabolites. Implications for neurodegenerative disease. FEBS Lett (1994) 1.23
Cognitive functioning in children on dialysis and post-transplantation. Pediatr Transplant (2000) 1.22
Percutaneous versus open tracheostomy: a retrospective cohort outcome study. J Trauma (1996) 1.22
Levodopa in the treatment of Parkinson's disease. Eur J Neurol (2009) 1.21
Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol (1992) 1.19
The calcium binding sites of synaptic vesicles of the frog sartorius neuromuscular junction. J Cell Biol (1974) 1.18
Mitochondrial function, GSH and iron in neurodegeneration and Lewy body diseases. J Neurol Sci (1998) 1.18
Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov Disord (1994) 1.18
Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease. J Neural Transm (Vienna) (1997) 1.18
An empirical analysis of stressors for gay men and lesbians. J Homosex (2001) 1.17
Molecular genetic analysis of von Hippel-Lindau disease. J Intern Med (1998) 1.17
Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol (1998) 1.16
The genetic basis of rheumatoid arthritis. The shared epitope hypothesis. Rheum Dis Clin North Am (1992) 1.15
Complex I, iron, and ferritin in Parkinson's disease substantia nigra. Ann Neurol (1994) 1.15
Striatal dopamine receptors become supersensitive while rats are geven trifluoperazine for six months. Nature (1979) 1.14
Formation of chimeric DNA primer extension products by template switching onto an annealed downstream oligonucleotide. Proc Natl Acad Sci U S A (1996) 1.13
Effect of the overexpression of wild-type or mutant alpha-synuclein on cell susceptibility to insult. J Neurochem (2001) 1.12
The analysis of nicotine-1'-N-oxide in urine, in the presence of nicotine and cotinine, and its application to the study of in vivo nicotine metabolism in man. J Pharm Pharmacol (1971) 1.11
Identification of permanent hearing loss in children: are the targets for outcome measures attainable? Br J Audiol (1999) 1.11
Altered 5-HT metabolism with clonazepam, diazepam and diphenylhydantoin. J Pharm Pharmacol (1975) 1.10
The involvement of noradrenaline in motor activity as shown by rotational behaviour after unilateral lesions of the locus coeruleus. Brain (1976) 1.09
Chondrogenic differentiation of adult dermal fibroblasts. Ann Biomed Eng (2004) 1.09
Proteasomal activity in brain differs between species and brain regions and changes with age. Mech Ageing Dev (2005) 1.08
Differential effects of continuous administration for 1 year of haloperidol or sulpiride on striatal dopamine function in the rat. Psychopharmacology (Berl) (1984) 1.08
Manipulation of brain serotonin in the treatment of myoclonus. Lancet (1975) 1.07
Selective inhibition of alternative oxidative pathways of nicotine metabolism. Chem Biol Interact (1971) 1.07
Do thermodynamic studies provide information on both the binding to and the activation of dopaminergic and other receptors? Biochem Pharmacol (1987) 1.07
In-vitro activity of S. lavandulaefolia (Spanish sage) relevant to treatment of Alzheimer's disease. J Pharm Pharmacol (2001) 1.07
Multiple dopamine receptors in brain and the pharmacological action of substituted benzamide drugs. Acta Psychiatr Scand Suppl (1984) 1.06
Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Exp Neurol (2000) 1.06
Substituted benzamides as cerebral dopamine antagonists in rodents. Neuropharmacology (1977) 1.05
Safety of kidney biopsy in pediatric transplantation: a report of the Controlled Clinical Trials in Pediatric Transplantation Trial of Induction Therapy Study Group. Transplantation (1999) 1.05
Color Doppler imaging findings in patients with Budd-Chiari syndrome: correlation with venographic findings. AJR Am J Roentgenol (1993) 1.05
Functional bowel disorders in the geriatric patient: constipation, fecal impaction, and fecal incontinence. Am J Gastroenterol (2000) 1.04
Effect of dual-chamber pacing with automatic rate-drop sensing on recurrent neurally mediated syncope. Am J Cardiol (1998) 1.04
Gastrointestinal manifestations of scleroderma. Rheum Dis Clin North Am (1996) 1.03
Alterations in surgical decision making in patients with cerebral palsy based on three-dimensional gait analysis. J Pediatr Orthop (1998) 1.03
A human intracellular apyrase-like protein, LALP70, localizes to lysosomal/autophagic vacuoles. J Cell Sci (1999) 1.03
Lipid peroxidation as cause of nigral cell death in Parkinson's disease. Lancet (1986) 1.03
Mitochondrial function and parental sex effect in Huntington's disease. Lancet (1990) 1.03
Cocaethylene: a unique cocaine metabolite displays high affinity for the dopamine transporter. J Neurochem (1991) 1.03